Medical cannabis patients across legal states are running into an unexpected barrier: their own doctors won't discuss it. Dr. Joseph Rosado, a medical cannabis expert, has identified the root causes and developed a framework to break the silence.
The problem stems from three interconnected issues, according to Rosado. Medical schools still don't teach cannabis pharmacology in most curricula, leaving physicians without the knowledge base they need. Legal concerns persist even in states with established medical programs. And stigma from decades of prohibition continues to influence clinical decision-making.
"Doctors aren't trained on this in medical school," Rosado explained, pointing to a gap that leaves even well-intentioned physicians unable to provide guidance. The result: patients who qualify for medical cannabis programs end up navigating treatment options alone, often relying on dispensary staff rather than medical professionals.
What the Evidence Shows
The research landscape for medical cannabis has evolved significantly over the past decade. Studies now support cannabis use for chronic pain, chemotherapy-induced nausea, and certain seizure disorders. But physicians hesitant to discuss these findings with patients create an information vacuum.
Rosado has developed five specific questions patients can ask to shift the conversation from avoidance to clinical assessment. These questions focus on benefits, risks, drug interactions, dosing considerations, and monitoring protocols. By framing the discussion around established medical evaluation standards, patients can prompt doctors to engage professionally rather than dismissing the topic outright.
The approach mirrors how physicians handle other treatments with complex risk-benefit profiles. Instead of asking "Can I use cannabis?" patients ask about specific mechanisms, potential contraindications with current medications, and what symptoms might indicate problems.
The Training Problem
Medical education remains a significant bottleneck. A 2020 survey found that only 9% of medical schools included cannabis science in their pharmacology courses. That means most practicing physicians graduated without any formal instruction on endocannabinoid systems, cannabinoid receptors, or therapeutic applications.
Younger physicians show more willingness to discuss medical cannabis, but they often lack the clinical experience to provide detailed guidance. Older physicians may have more clinical judgment but carry more stigma from their training era. Both groups face the same legal uncertainty about their role in recommending a federally prohibited substance.
Some states have tried to address this through continuing medical education requirements for doctors who certify patients. But those programs typically focus on state law compliance rather than clinical pharmacology.
Changing the Conversation
Rosado's five-question framework gives patients a script that transforms the dynamic. Instead of putting doctors on the defensive about cannabis generally, it asks them to apply their existing medical expertise to a specific treatment consideration.
The questions cover drug interaction screening, contraindications based on medical history, appropriate delivery methods for specific conditions, signs of adverse effects to monitor, and how to assess whether the treatment is working. These are standard clinical evaluation steps physicians perform for any medication.
Patients in the 38 states with medical cannabis programs can use this approach even if their regular physician won't serve as their certifying doctor. The goal isn't necessarily to get a recommendation from that specific physician, but to ensure medical oversight of the treatment plan.
What's Next
As federal rescheduling discussions continue, medical education institutions are starting to respond. Several pharmacy schools now offer elective courses in cannabis pharmacology. Medical residency programs in states with established programs are beginning to include cannabis in pain management rotations.
But change remains slow. Until medical schools integrate cannabis science into core curricula, patients will need strategies like Rosado's to bridge the knowledge gap. The five-question approach offers a practical tool while the medical establishment catches up to state-level policy changes.
For now, patients face a choice: accept physician silence or use structured questions to prompt clinical engagement. Rosado's framework suggests the latter can work, even when doctors remain uncomfortable with the topic.
This article is based on original reporting by hightimes.com.
